Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the 2024 Profit Distribution Plan of the Company

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR- JOINCARE Announcement on the Capital Increase of The Holding Sub-Subsidiary

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2025 First Extraordinary General Meeting

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Progesterone Injection

Time:2025-03-24

Ad hoc announcement pursuant to Art. 53 LR-JOINCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-02-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance for Registration and Market Authorization Application of Recombinant Human Follitropin Alfa Solution for Injection

Time:2025-01-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Provision for Impairment of Assets

Time:2025-01-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial

Time:2024-12-19

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Time:2024-11-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Fifth Extraordinary General Meeting

Time:2024-11-25

< 1234...12 >